A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase
Phase III

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
PRE21-005302
Category
Hematology-Oncology
Oncology
Contact
Kimberly Kelly
Location
  • TRIO-US - Ft. Wayne IN
  • TRIO-US - Jonesboro AR
  • TRIO-US - Los Alamitos CA
  • TRIO-US - Whittier